DNA (Ginkgo Bioworks Holdings) Short-Term Debt: $0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DNA Ginkgo Bioworks Holdings Inc DNA
60 GF Score
Price $6.53
GF Value $5.96
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Ginkgo Bioworks Holdings Short-Term Debt?

Ginkgo Bioworks Holdings DNA -5.64% 60 Short-Term Debt is $0.0 Mil as of Jun. 2026. GuruFocus rates DNA with a GF Score™ of 60/100 and a GF Value™ of $5.96 (Fairly Valued). The stock has 5 warning signs investors should review.

Ginkgo Bioworks Holdings's Short-Term Debt for the quarter that ended in Jun. 2026 was $0.0 Mil.

Ginkgo Bioworks Holdings Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Ginkgo Bioworks Holdings Short-Term Debt Related Terms

Ginkgo Bioworks Holdings Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Ginkgo Bioworks Holdings's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ginkgo Bioworks Holdings Short-Term Debt Chart

Ginkgo Bioworks Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Ginkgo Bioworks Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
DNA
60GF Score
Ginkgo Bioworks Holdings Inc DNA
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.0 Mil mean?
Ginkgo Bioworks Holdings (DNA) has a Short-Term Debt of $0.0 Mil as of Jun. 2026.
Is Ginkgo Bioworks Holdings' Short-Term Debt too high?
Ginkgo Bioworks Holdings' current Short-Term Debt is $0.0 Mil. Overall, Ginkgo Bioworks Holdings has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ginkgo Bioworks Holdings' Short-Term Debt compare to RZLT and EIKN?
Ginkgo Bioworks Holdings' Short-Term Debt of $0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Ginkgo Bioworks Holdings's current Short-Term Debt is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ginkgo Bioworks Holdings stock overvalued right now?
Based on GuruFocus' analysis, Ginkgo Bioworks Holdings (DNA) is currently considered Fairly Valued. The stock's GF Value™ is $5.96, compared to a current price of $6.53 — trading 9.6% above its estimated fair value. The current Short-Term Debt is $0.0 Mil. Ginkgo Bioworks Holdings' overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Ginkgo Bioworks Holdings (DNA), the current Short-Term Debt is $0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ginkgo Bioworks Holdings (DNA) Overvalued in 2026?

Based on GuruFocus' analysis, Ginkgo Bioworks Holdings stock appears to be overvalued. The current stock price of $6.53 is trading 9.6% above its estimated GF Value™ of $5.96. GuruFocus considers Ginkgo Bioworks Holdings to be Fairly Valued.

Key valuation signals for DNA:

  • Short-Term Debt: $0.0 Mil
  • GF Value™: $5.96 vs. price of $6.53 (9.6% above fair value)
  • GF Score™: 60/100 with 5 warning signs

No single metric tells the full story. See the DNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ginkgo Bioworks Holdings Business Description

Other Exchanges DNA:Mexico
Address 27 Drydock Avenue, 8th Floor, Boston, MA, USA, 02210
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
60GF Score

Get the complete analysis for DNA

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.53
Price
$5.96
GF Value